LCMT1抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P01509(LCMT1 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P01509(LCMT1 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The LCMT1 (leucine carboxyl methyltransferase 1) antibody is a tool used to study the enzyme LCMT1. which plays a critical role in post-translational modification of protein phosphatase 2A (PP2A), a major serine/threonine phosphatase involved in cellular signaling. LCMT1 catalyzes the methylation of the PP2A catalytic subunit (PP2Ac) at its C-terminal leucine residue, a modification essential for the assembly and functional specificity of PP2A holoenzymes. These holoenzymes regulate diverse processes, including cell cycle progression, apoptosis, and metabolic pathways. Dysregulation of PP2A methylation, mediated by LCMT1. has been linked to cancers, neurodegenerative diseases, and developmental disorders.

Antibodies targeting LCMT1 are primarily used in research to investigate its expression, localization, and interaction partners in various biological contexts. They enable detection via techniques like Western blotting, immunofluorescence, and immunoprecipitation. Such studies help elucidate LCMT1's regulatory mechanisms, including its role in maintaining PP2A activity and its crosstalk with other methylation pathways. Commercially available LCMT1 antibodies are typically raised in rabbits or mice, with validation in knockout models or siRNA-treated cells to confirm specificity. Their application has advanced understanding of how LCMT1 dysfunction contributes to disease pathogenesis, particularly in cancer, where PP2A acts as a tumor suppressor. Ongoing research continues to explore LCMT1 as a potential therapeutic target.